TCM Biotech International (ROCO:4169) EBIT : NT$24.8 Mil (TTM As of Dec. 2023)

View and export this data going back to 2012. Start your Free Trial

What is TCM Biotech International EBIT?

TCM Biotech International's earnings before interest and taxes (EBIT) for the six months ended in Dec. 2023 was NT$13.5 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Dec. 2023 was NT$24.8 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. TCM Biotech International's annualized ROC % for the quarter that ended in Dec. 2023 was 2.82%. TCM Biotech International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 4.61%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. TCM Biotech International's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Dec. 2023 was 0.85%.

TCM Biotech International EBIT Historical Data

The historical data trend for TCM Biotech International's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

TCM Biotech International EBIT Chart

TCM Biotech International Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

EBIT

Get a 7-Day Free Trial

15.12

38.08

4.23

25.51

24.80

TCM Biotech International Semi-Annual Data
	Jun14	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23
EBIT	Get a 7-Day Free Trial															2.66	17.99	7.52	11.35	13.45

Competitive Comparison of TCM Biotech International's EBIT

For the Biotechnology subindustry, TCM Biotech International's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

TCM Biotech International's EV-to-EBIT Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, TCM Biotech International's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where TCM Biotech International's EV-to-EBIT falls into.

TCM Biotech International EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Dec. 2023 adds up the semi-annually data reported by the company within the most recent 12 months, which was NT$24.8 Mil.

TCM Biotech International (ROCO:4169) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

TCM Biotech International's annualized ROC % for the quarter that ended in Dec. 2023 is calculated as:

	ROC % (Q: Dec. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Dec. 2023 ))	/ count )
=	22.44 * ( 1 - 16.63% )	/	( (643.937	+	683.015)	/ 2 )
=	18.708228	/	663.476
=	2.82 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	854.883	-	141.273	-	( 69.673	-	max(0, 215.3	-	509.019	+	69.673	))
=	643.937

	Invested Capital		(Q: Dec. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	1322.922	-	135.776	-	( 504.131	-	max(0, 198.378	-	981.153	+	504.131	))
=	683.015

Note: The Operating Income data used here is two times the semi-annual (Dec. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

TCM Biotech International's annualized ROC (Joel Greenblatt) % for the quarter that ended in Dec. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Dec. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Dec. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	26.906	/	( ( (298.934 + max(266.715, 0))	+	(293.711 + max(307.319, 0)) )	/	2 )
=	26.906	/	( ( 565.649	+	601.03 )	/	2 )
=	26.906	/	583.3395
=	4.61 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(221.13	+	168.065	+	23.758)	-	(141.273	+	0	+	4.965)
=	266.715

	Working Capital		(Q: Dec. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(232.395	+	181.734	+	32.596)	-	(135.776	+	0	+	3.63)
=	307.319

When net working capital is negative, 0 is used.

Note: The EBIT data used here is two times the semi-annual (Dec. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

TCM Biotech International's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Dec. 2023 )
	=	24.804	/	2902.446
	=	0.85 %

TCM Biotech International EBIT Related Terms

Thank you for viewing the detailed overview of TCM Biotech International's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

TCM Biotech International (ROCO:4169) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » TCM Biotech International Corp (ROCO:4169) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

N/A

Address

No. 97, Sec. 1, Xintai 5th Road, Xizhi District, Neihu District, Taipei, TWN, 221

Website

http://www.tcmbio.com

TCM Biotech International Corp is a Taiwan based biotechnology company. It is engaged in the research and development of therapeutics for the prevention and treatment of liver diseases. Its products includes Anti-adhesion System, Anti-neoplastic agents, Osteoporosis Treatment Preparation, Iron Preparations, Osteoarthritis (OA) Treatment Products, Urinary System Treatment Products and others. The company has a business presence in Taiwan and other international countries such as the United States, Japan, Singapore, Malaysia, Vietnam, the Philippines and China. The entity derives key revenue from the sales of multiple medical products which includes medicine, medical device, functional food and others.

TCM Biotech International (ROCO:4169) Headlines

No Headlines